Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (OP: NUMIF ) 0.0237 +0.0015 (+6.76%) Streaming Delayed Price Updated: 2:46 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 59,235 Open 0.0237 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0222 Today's Range 0.0222 - 0.0252 52wk Range 0.0180 - 0.1800 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit July 12, 2024 Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024."In... Via Benzinga Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition June 22, 2024 Psychedelics-focused mental healthcare company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) plans to take over MedBright AI Investments Inc. (CSE: MBA).The proposed transaction comes as... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Performance YTD -73.22% -73.22% 1 Month -18.56% -18.56% 3 Month -53.44% -53.44% 6 Month -71.06% -71.06% 1 Year -82.46% -82.46% More News Read More Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends April 15, 2024 Via Benzinga Two Top Biotechs Forge MDMA Supply Deals For Clinical Research March 26, 2024 Via Benzinga Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions March 25, 2024 Via Benzinga Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review March 16, 2024 Via Benzinga Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More February 15, 2024 Via Benzinga Why Is MindMed (MNMD) Stock Up 8% Today? February 12, 2024 Via InvestorPlace Exposures Product Safety Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More January 27, 2024 Via Benzinga Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway January 18, 2024 Via Benzinga 30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond January 10, 2024 Via Benzinga Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More December 05, 2023 Via Benzinga Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate November 30, 2023 Via Benzinga Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News September 15, 2023 Via Benzinga NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years September 12, 2023 Via Benzinga Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 July 26, 2023 Via FinancialNewsMedia Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing July 14, 2023 From Virtual Investor Conferences Via GlobeNewswire Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th July 10, 2023 From Virtual Investor Conferences Via GlobeNewswire MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University June 20, 2023 Via Benzinga Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study June 16, 2023 Via Benzinga Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study June 05, 2023 Via Benzinga Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More May 31, 2023 Via Benzinga Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD May 30, 2023 Via Benzinga Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More April 24, 2023 Via Benzinga Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network April 19, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.